Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

NCT07030283 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

DRUG: Paclitaxel
DRUG: NALIRIFOX

Sponsor

University of Colorado, Denver